EUVIMEDEUVIMED entdecken
Crossref

Apremilast for the treatment of psoriasis and psoriatic arthritis

Steve Chaplin

Future Prescriber · 2013

DOI: 10.1002/fps.102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Prescriber, 2013. Verfasst von Steve Chaplin.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apremilast, an orally active inhibitor of phosphodiesterase 4 that inhibits several inflammatory cytokines, is being developed for the treatment of psoriasis and psoriatic arthritis. This Drug profile reviews the clinical data to date. Copyright © 2013 John Wiley & Sons, Ltd.

Zitieren

APA

Chaplin, S. (2013). Apremilast for the treatment of psoriasis and psoriatic arthritis. Future Prescriber. https://doi.org/10.1002/fps.102

Vancouver

Chaplin S. Apremilast for the treatment of psoriasis and psoriatic arthritis. Future Prescriber. 2013. doi:10.1002/fps.102

BibTeX
@article{Chaplin2013,
  author = {Chaplin, Steve},
  title = {Apremilast for the treatment of psoriasis and psoriatic arthritis},
  journal = {Future Prescriber},
  year = {2013},
  doi = {10.1002/fps.102}
}
Kostenlos starten →